ArticleEClinicalMedicine2026
Mental health treatment among transgender and gender diverse people following gender affirming hormone therapy: evidence from whole-of-population Australian administrative data.
Article in EClinicalMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Healthcare Costs Following Medical Gender-Affirmation: Evidence From Whole-of-Population Australian Administrative Data.Health economics · 2026Article
- All-cause and cause-specific mortality among transgender and gender diverse people: a nationwide cohort study in Australia.The Lancet regional health. Western Pacific · 2026Article
- Mental health treatment among transgender and gender diverse people following gender affirming hormone therapy: evidence from whole-of-population Australian administrative data.EClinicalMedicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gender affirming hormone therapy (GAHT) is associated with improved mental health outcomes among transgender and gender diverse ('trans') individuals, yet limited evidence examines how mental healthcare utilisation changes following GAHT initiation. Methods: Using Australian administrative data (2012-2024), we identified trans people initiating oestradiol-based GAHT (e-GAHT) or testosterone-based GAHT (t-GAHT). We applied a dynamic difference-in-differences model to estimate within-individual changes in mental health services and prescriptions (antidepressants, anxiolytics), using future GAHT recipients as controls. Effects were estimated separately by regimen and relative to individuals' utilisation three years before GAHT initiation, up to five years post-initiation, and stratified by age (15-24, ≥25 years) and baseline mental healthcare engagement (above/below mean mental health prescription use). Findings: 20,358 individuals initiated e-GAHT and 11,883 initiated t-GAHT (mean follow-up 4.1 and 4.9 years, respectively). Prior to initiation, e-GAHT recipients had lower engagement with mental healthcare than t-GAHT recipients. For both regimens, mental healthcare use rose at initiation but declined sharply thereafter, with larger initial increases for e-GAHT recipients. Five years post-initiation, e-GAHT and t-GAHT recipients used 0.29 (95% CI -0.03; 0.60) and 2.59 (95% CI 1.87; 3.31) fewer mental health services, respectively. Mental health prescription use among e-GAHT recipients initially rose and then fell to 0.53 (95% CI 0.20; 0.86) at five years, while t-GAHT recipients used 1.02 (95% CI 0.31; 1.72) fewer prescriptions after five years. Reductions in mental healthcare were more pronounced for individuals with higher baseline mental healthcare engagement as well as older e-GAHT recipients. Interpretation: Consistent with assessment and support requirements, mental healthcare use increases around the time of GAHT initiation-particularly among individuals with limited prior mental healthcare engagement and younger e-GAHT recipients-then declines substantially over time. Altogether GAHT may help address unmet mental health needs and contribute to longer-term reductions in mental healthcare use and associated costs among trans people. Funding: This work is supported by the University of Melbourne McKenzie Fellowship (2025MCK182), a Viertel Charitable Foundation Clinical Investigator Award, and a National Health and Medical Research Council Investigator Grant (2034450).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.